STOCK TITAN

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

CANTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the following upcoming investor conferences:

The Morgan Stanley 18th Annual Global Healthcare Conference

  • Management will participate in a fireside chat on Wednesday, September 16 at 5:00 p.m. Eastern Time.

The Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

  • Management will participate in a fireside chat on Tuesday, September 22 at 4:10 p.m. Eastern Time.

Live audio webcasts of the conference presentations will be accessible by visiting the “Upcoming Events” section on the “Investor Relations” page of Organogenesis’s website www.organogenesis.com. An archive of the webcast will be available for replay following the conference for approximately 30 days.

About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.

 
Organogenesis Holdings Inc.

NASDAQ:ORGO

ORGO Rankings

ORGO Latest News

ORGO Stock Data

363.25M
61.84M
33.32%
44.97%
5.48%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
CANTON

About ORGO

headquartered in canton, massachusetts, organogenesis inc. is a global leader in regenerative medicine, offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. organogenesis’ versatile portfolio is designed to treat a variety of patients with repair and regenerative needs.